Bryan Johnson· Author
Tirzepatide didn't work for me. I'm already top 1% on glucose control and body composition, so the marginal upside was small. And even at 20% of the starting dose (0.5 mg/week), my resting HR climbed 2–3 bpm.
Loading…
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
Tirzepatide didn't work for me. I'm already top 1% on glucose control and body composition, so the marginal upside was small. And even at 20% of the starting dose (0.5 mg/week), my resting HR climbed 2–3 bpm.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Tirzepatide didn't work for me. I'm already top 1% on glucose control and body composition, so the marginal upside was small. And even at 20% of the starting dose (0.5 mg/week), my resting HR climbed 2–3 bpm.
I am halting Tirzepatide microdosing because it increased my resting heart rate by 3 bpm, lowered my HRV by 7 and decreased my sleep quality by 10%
Only the non-metabolic longevity benefits are applicable in my case, these were very recently identified, with only a handful of studies supporting them.
Verdict: the risk/harm outweighs the benefit, for the following reasons
I am halting Tirzepatide microdosing because it increased my resting heart rate by 3 bpm, lowered my HRV by 7 and decreased my sleep quality by 10%
I am halting Tirzepatide microdosing because it increased my resting heart rate by 3 bpm, lowered my HRV by 7 and decreased my sleep quality by 10%
Verdict: the risk/harm outweighs the benefit, for the following reasons